News und Analysen

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core⁽¹⁾ compared to the second quarter

Agilent Technologies Inc. (NYSE: A) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent’s board of directors.

Bishop joined

Agilent Technologies Inc., (NYSE: A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system

Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on July 24, 2024, to all shareholders of record as of the close of

Agilent Technologies Inc., (NYSE: A) will showcase its latest mass spectrometry innovations at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, scheduled for June 2 - 6, 2024, in

Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 5, at

Agilent Technologies Inc. (NYSE: A) today announced two Solutions Innovation Research Awards (SIRA) presented to Professors Richard Robinson of Cornell University and Xingchen Ye of Indiana

CenterWell Specialty Pharmacy has received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the sixth time in seven years. The award recognizes best-in-class customer

Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s

Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a

Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted⁽³⁾ diluted EPS guidance while maintaining all other components of its 2024 financial

Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full

Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO^® (aztreonam-avibactam) for the treatment of adult patients with

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at

Agilent Technologies Inc. (NYSE: A) announces that it is the recipient of two 2023 Sustainability Scientists’ Choice awards — Sustainable Supplier of the Year and Sustainable Product of the Year

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April

Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at

Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows. Analytica, the premier

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR). At

Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana, announced it is partnering with CPESN^® USA in Ohio to expand access to pharmacists for its members